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Abstract A simple and sensitive method has been developed
and validated for the determination of aliskiren (ALS) in its
dosage forms and spiked plasma. The method was based on
the reactionofthe drugwithdansylchlorideinthe presenceof
bicarbonate solution of pH 10.5 to give a highly fluorescent
derivative which was measured at 501 nm with excitition at
378 nm in dichloromethane. Different experimental parame-
ters affecting the development of the method and stability
were carefully studied and optimized. The calibration curves
were linear over the concentration ranges of 100–700 and 50–
150ng/mLforstandardsolutionandplasma,respectively.The
limits of detection were 27.52 ng/mL in standard solution,
4.91 ng/mL in plasma. The developed method was success-
fully applied to the analysis the drug inthe commercial tablets
and spiked plasma samples. The mean recovery of ALS from
tablets and plasma was 100.10 and 97.81%, respectively. A
proposal of the reaction pathway was presented.
Keywords Aliskiren.Dansyl chloride.
Spectrofluorimetry.Tablets.Spiked plasma
Introduction
Aliskiren hemifumarate [(2S,4S,5S,7S)-N-(2-carbamoyl-2-
methyl propyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-
methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemi-
fumarate] (ALS) is a direct renin enzym inhibitor and
recently has been approved for the treatment of essential
hypertension [1–3].
There is no official analytical method for analysis of ALS.
Literature survey revealed that a some analytical methods
(mostly for investigation of pharmacokinetics properties of
drug) for determination of ALS in serum and plasma have
been reported. These methods include radioimmunoassay [4],
heigh performance liquid chromatography (HPLC) [5], heigh
performance liquid chromatography/mass spectrometry
(HPLC/MS) [6–9], HPLC/MS/MS [1–3] detection. There
are only two HPLC [10, 11] and a spectrophotometric
methods [10] for the determination of the drug in pharma-
ceutical dosages. The HPLC coupled with mass spectrometry
methods offered the required sensitivity for the analysis of
ALS in biological fluids; however their sophisticated
instrumentation and high analysis cost limited their use for
analysis of drugs. The reported spectrophotometric and
HPLC medhods for estimation of ALS in tablets [10]a r e
not sensitive enough with the initial determined concentration
of analyte (40 and 25 μg/mL, respectively) and the method
may not also apply to analysis of drug in biological fluids.
Moreover,thevalidationresultswerenotgiveninthe reported
HPLC method [10, 11]. Although, spectrofluorimetry is a
sensitive, selective and simple technique, however up to
now, no method has been reported for the determination of
ALS in tablets and human plasma by spectrofluorimetry. For
these reasons, and novelty of the drug, the development of
new sensitive and simple spectrofluorimetric method is very
essential. DNS-Cl is known to react with primary, secondary
amines, imidazoles, thiols, phenolic and alcoholic hydroxyl
groups and carboxylic acid groups [12–14]. DNS-Cl has
been used as a fluorogenic reagent for the determination of
many pharmaceutical compounds [15–17].
The present study describes a simple, sensitive, fast and
cheap spectrofluorometric method for the analysis of ALS
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DOI 10.1007/s10895-011-0988-yin its tablets and spiked plasma samples. The developed
method was based on its reaction with dansyl chloride
(DNS-Cl) in bicarbonate solution of pH 10.50, to form
fluorescent product which was measured fluorometrically at
501 nm (λex 378 nm).
Experimental
Apparatus
Shimadzu RF-1501 (Tokyo, Japan) spectrofluorometer and
ShimadzuUV-160(Tokyo,Japan)UV–visspectrophotometer
were used. One centimeter path length quartz cells were used.
pH measurements were made with WTWpH 526 digital pH
Meter.
Materials and Reagents
All reagents and solvents were of analytical reagent grade.
ALS was kindly supplied by Novartis Pharmaceutical
(Istanbul-Turkey) and its film-coated Tekturna® tablets con-
taining 150 mg and 300 mg of ALS were obtained from local
pharmacy in Chicago-USA. 5- dimethylaminonaphthalene-1-
sulphonyl chloride (DNS-Cl) purchased from Sigma-Aldrich
(Germany). Solution of DNS-Cl was freshly prepared at
2.0 mg/ml in acetonitrile.
The sodium bicarbonate (0.025 M) solution was prepared
in water and adjusted pH to 10.5 with 0.1 M sodium
hydroxide using a pH meter. This solution was kept in
refrigerator and used for about 1 week.
Water was purified by aquaMAXTM-ultra, Young-lin
instrument (Korea) ultrawater purification system.
Solutions
A stock solution at 1.0 mg/mL (concentration expressed as
base compound) was prepared in water. This stock solution
was further diluted with water to obtain standard solutions
at 0.01 mg/mL. The solutions were stable for at least one
month when kept in the refrigerator.
General Procedures
Procedure for Calibration Curve
Aliquots of 50.0–350.0 μL of standard drug solutions
(0.01 mg/mL) were transferred into a series of 10 mL
stoppered glass tubes. A 300 μL of bicarbonate solution at
pH 10.5 and 300 μL of DNS-Cl solution were added to each
tube and the mixture was left for 20 min at 30 °C in the dark.
Then, the derivative was extracted with 5 mL of dichloro-
Table 1 The maximum excitation and emission wavelength of the
ALS-DNS derivatization products in different organic extraction
solvents. [ALS]=800 ng/mL
Extraction Solvent λex/λem (nm) Fluorescence intensity
Dichloromethane 378/501 918.419
Chloroform 381/494 481.264
Carbon tetrachloride 372/497 402.594
Diethyl ether 385/489 356.814
Fig. 1 Effect of the pH on the development of the reaction product of
ALS (800 ng/mL) with DNS-Cl
Fig. 2 Effect of temperature on the reaction of ALS (800 ng/mL) with
DNS-Cl
Fig. 3 Emission spectrum of the reaction product of ALS (350 ng/mL)
with DNS-Cl (λex=378 nm, λem=501 nm) in dichloromethane
550 J Fluoresc (2012) 22:549–556methane by a vortex mixer. The organic layer was separated
and dried over anhydrous sodium sulfate. The fluorescence
intensity of the resulting solution was measured at 501 nm
after excitation at 378 nm. Blank experiment was carried out
simultaneously. The corrected fluorescence intensity was
plotted versus the final drug concentrations to get the
calibration curve. The corresponding regression equation
was derived.
Procedure for Spiked Human Plasma
Drug free human plasma was obtained from Istanbul
University Cerrahpasa Hospital (Istanbul, Turkey) and
stored at −20 °C until analysis and thawed to room
temperature before use. A 0.5 mL aliquot of human
plasma was transferred into a series of centrifuge tubes
and spiked with different concentration of ALS to give
a final concentration range of 50–150 ng/mL (Table 1).
Extraction with 1.0 mL acetonitrile was performed to
precipitate plasma proteins, followed by centrifugation at
4,500 rpm for 20 min. The resulting supernatant was
evaporated to dryness under nitrogen at 40 °C. The
residual mass was reconstituted with 0.1 mL water and
then the analyses were performed as under “Procedure for
Calibration Curve”.
All the procedures for blank were performed in the same
manner. The corrected fluorescence intensity was measured
at excitation wavelength of 378 nm and emission wave-
length of 501 nm respectively.
Procedure for Tablet Formulations
Ten Tekturna tablets containing 150 and 300 mg ALS
were weighed and powdered separately. From each of
the powdered tablet forms, an amount of the powder
equivalent to 150 and 300 mg ALS were transferred to
100 mL volumetric flasks seperately. About 50 mL of
water was added and then extraction was performed
mechanically for 1 h. The volumes were brought to
100 mL with water and final solution was filtered. For
both tablet solution, aliquot covering the working
concentration range (cited in Table 1) was trasferred
into glass tubes and analyzed separately as described
under “Procedure for Calibration Curve” section.
The nominal content of the tablets was determined using
the corresponding regression equations of the calibration
curves.
Determination of the Stoichiometric Ratio of the Reaction
The reaction stoichiometry between ALS and DNS-Cl was
determined by Job’s continuous variation method. The drug
solution with identical molar concentrations of reagent
(2.5×10
−4 M) were mixed in varying volume ratios ((5:1,
4.8:1.2, …, 1.2:4.8, 1:5) in which the total volume of the
mixtures were kept at 6.0 mL, and the procedures were
completed as described for the calibration curve. The
fluorescence intensity values obtained were plotted against
the mole fraction of the drug solution. Each determination
was carried out in triplicate.
Results and Discussion
Optimization of Experimental Parameters
The different experimental parameters affecting the
development of the reaction product and its stability
were studied and optimized for the spectrofluorimetric
method. Such factors were changed individually while
others were kept constant. These factors include pH,
type of buffer, amounts of reagent, temperature, reaction
time and effect of solvent.
Effect of pH
The influence of pH on the fluorescence intensity of the
reaction product was examined using bicarbonate solu-
Fig. 4 Excitation spectrum of the reaction product of ALS (350 ng/
mL) with DNS-Cl (λex=378 nm, λem=501 nm) in dichloromethane
Fig. 5 Stoichiometry of the reaction between ALS and DNS-Cl
adopting Job’s method of continuous variation
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11.0 since DNS-Cl reacts under alkaline conditions. The
maximum fluorescence intensity was obtained when the
reaction was carried out with bicarbonate solution of pH
10.5 (Fig. 1) and the optimum volume of this solution
was 0.3 mL.
Fig. 6 IR spectrum of ALS
Fig. 7 IR spectrum of derivati-
zation of drug with DNS-Cl
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The effect of the concentration of DNS-Cl was studied using
different volumes of the reagent at 2 mg/mL solution (varied
from 50 mL to 350 μL). It was found that increasing the
volume of the reagent produces a proportional increase in the
fluorescence intensity of the reaction product up to 300 μL.
However, nofurther increaseinthe fluorescenceintensity was
observed upon increasing the volume of the reagent up to
350 μL. Therefore, 300 μL of 2 mg/mL of DNS-Cl solution
was chosen for derivatization reaction.
Effect of Reaction and Heating Time
Different reaction times (5–30 min) and temperatures (at
room and 30–60 °C) were studied to obtain highest
fluorescence intensity of the reaction product. It was found
that the reaction product reached the highest fluorescence
within 20 min at 30 °C. The effect of temperature on the
reaction of ALS with DNS-Cl was shown in Fig. 2.
Effect of Extraction Solvent
In order to avoid the interference of the highly fluorescent
dansyl hydroxide formed in the dansylation reaction
medium, which is polar character and remains in the
aqueous phase, the derivatization product was extracted
with immiscible organic solvent for spectrofluorimetric
method. For this purpose, different solvents including
tetrachloromethane, diethyl ether, dichloromethane and
Table 2 Statistical parameters for analysis of derivatives of ALS with
DNS-Cl
Parameters Standard solution Plasma
Linearity range
a
(ng/mL)
100.0–700.0 50–150
λex/λem (nm) 378/501 378/501
Regression equation
b
Slope ± SD 1.0051±0.012 6.9638±0.07
Intercept ± SD 94.4392±9.22 −216.86±10.79
Correlation
coefficient (r)
0.9998 0.9986
LOD (ng/mL) 27.53 4.91
LOQ (ng/mL) 91.76 16.37
aAverage of six and five determinations for the drug in standard
solution and plasma, respectively
bn=5 Correspond to replicate analysis for each level
bIf = aC + b (where C is the concentration of the drug in ng/mL, If is
the fluorescence intensity at emission wavelength
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obtained upon using dichloromethane (Table 1). The
emission and excitation spectrum of derivatization product
of ALS in dichloromethane are shown in Figs. 3 and 4. The
fluorescence intensity of the derivatization product in the
same solvent was stable for at least 24 h if stored in dark at
room temperature.
Stoichiometry and Mechanism of the Reaction
Under the selected conditions, the stoichiometry of the
reaction between ALS and DNS-Cl was studied by Job’s
method of continuous variation [18]. As shown in Fig. 5,
the stoichiometry of the reaction was found as 1:2 ratios
(drug/reagent), confirming that one molecule of ALS reacts
with two molecule of DNS-Cl.
ALS contains a primary aliphatic amine and secondary
hydroxyl group which are capable of acting as base and
involved nucleophilic reactions. Thus, the sulfonyl chloride
group of DNS-Cl can be attacked by these nucleophilic
groups. Also, the acidity of these groups plays an important
factor in the dansylation reaction. Comparison of acidity
based on pKa appears as follows: R-NH2 (pKa~36), ROH
(pKa~16), RNHR (pKa~11) [13]. Based on all these fact
and by the previous dansylation studies, it is concluded that
ALS in alkaline medium (pH=10.5) reacts with DNS-Cl
through its primary amino group and hydroxyl group. In
order to confirm the placement of dansyl moiety on drug,
IR spectra (Perkin–Elmer Universal ATR sampling acces-
sory apparatus) of ALS (Fig. 6) and derivatization product
(Fig. 7) which was prepared as the same manner of
described in experimental section were also recorded and
compared. IR spectrum did not provide more information
since several absorption bands for the stretching of O-H and
N-H bonds were observed in the same regions. However,
the extinction of characteristic O-H signal at 1,284 cm
−1
[19] in the IR spectrum of the reaction product provided
that one DNS moiety was attached to the drug molecule at
hydroxyl group.
A schematic proposal of the reaction pathway is given in
Scheme 1.
Analytical Performance
Linearity and Sensitivity
For evaluation of linearity at the selected conditions,
determination of ALS was carried out at six concentration
(n=6) and five concentration levels for standard solution
and plasma samples (n=5), respectively. The calibration
curves of ALS were linear over the concentration range of
100–700 ng/mL for standard solution and 50–150 ng/mL
for plasma samples.
The limit of detection (LOD) and limit of quantification
(LOQ) were calculated as 3Sb/m and 10Sb/m, respectively,
Sb is the standard deviation of the intercept of regression
line, and m is the slope of the calibratiom curve [20]. On
this basis, the LOD and LOQ of the proposed method for
standard drug analysis were 27.53 and 91.76 ng/mL for
ALS, respectively. The LOD and LOQ for plasma samples
were 4.91 and 16.37, respectively. The parameters for the
analytical performance of the proposed method are sum-
marized in Table 2.
Accuracy and Precision
Accuracy, intraday and interday precisions of the method
were determined. Five replicate spiked plasma samples in
the same day, as well as on five consecutive days were
assayed for intra-day and inter-day accuracy at three
different concentrations for each analyte. Accuracy was
calculated as deviation of the mean from the nominal
concentration. The intraday and interday precisions
(expressed as the relative standard deviation (RSD%) for
Table 3 Recovery of ALS
from standard samples
and plasma (n=5)
Amount added (ng/mL) Amount found (ng/mL) (Mean ± SD) Recovery (%) RSD (%)
Standard preparation
200.0 201.38±5.51 101.37 2.73
400.0 402.66±7.88 101.33 1.96
600.0 599.26±5.95 99.75 0.99
Plasma
50.0 48.04±2.52 96.08 2.14
100.0 98.59±4.62 98.59 0.98
150.0 148.13±4.51 98.75 0.55
Table 4 Results obtained for ALS determination in Tekturna tablets
(n=6)
Labelled amount Mean ± SD Recovery (%) RSD (%)
150 mg ALS 150.27±0.96 100.18 0.64
300 mg ALS 300.16±1.05 100.03 0.35
554 J Fluoresc (2012) 22:549–556ALS ranged from 0.47 to 2.51% and 0.58 to 2.19%,
respectively. The intraday and interday precisions for drug
in plasma ranged from 0.37 to 2.09% and 0.96 to 2.30%,
respectively.
Recovery
Recovery studies were carried, by spiking known different
amounts of pure drug solutions to the preanalysed drug
samples.The results given in Table3 revealed that the RSD%
and percent average of recovery for preparation samples
were in the range of 0.99–2.73%, 99.75–101.37%. Recovery
results suggest method to be unaffected in the presence of
formulation excipients and confirm the heigh accuracy.
The RSD% and percent average of extraction recoveryfor
ALS determined at different concentrations in plasma were
in the range of 0.55–2.14%, 96.08–98.75%, respectively
(Table 3).
Robustness
Robustness was examined by evaluating the influence of
small variations in the experimental conditions such as
working excitation and emission wavelengths (±3 nm),
volume of reagent (±5 μL), volume of bicarbonate solution
(±10 μL), change in pH (±0.2), the temperature degree and
heat time, which are applied for derivatization reaction
(±5 °C and ±5 min). These minor changes that may take
place during the experimental operation did not have any
significant effect on fluorescence intensity of the reaction
product. RSD% for the measured fluorescence intensity
after the studied variations did not exceed 4.50%.
Application to Tablets
The proposed method was successfully applied to analysis
of two different commercial tablets (Tekturna Tablets)
which contain 150 and 300 mg ALS. The mean recovery
values of tablets that were contained 150 mg and 300 mg
ALS were 100.18% and 100.03%, respectively (Table 4).
Conclusion
The proposed spectrofluorimetric method has the advan-
tage of being simple, fast, highly sensitive, accurate,
low cost, and do not require any pretreatment of the
drug and tedious extraction procedure. The method was
successfuly applied for determining ALS in tablets and
spiked plasma without any interference from excipients.
Therefore, the developed method can be suitable for
routine analysis of ALS in quality control laboratories
and clinical laboratories.
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